75 related articles for article (PubMed ID: 7518926)
1. Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].
Szepeshazi K; Schally AV; Keller G; Block NL; Benten D; Halmos G; Szalontay L; Vidaurre I; Jaszberenyi M; Rick FG
Oncotarget; 2012 Jul; 3(7):686-99. PubMed ID: 22824624
[TBL] [Abstract][Full Text] [Related]
2. EGF-Enhanced GnRH-II Regulation in Decidual Stromal Cell Motility through Twist and N-Cadherin Signaling.
Wu HM; Chen LH; Huang HY; Wang HS; Tsai CL
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894950
[TBL] [Abstract][Full Text] [Related]
3. Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer.
Gründker C; Emons G
Cells; 2021 Feb; 10(2):. PubMed ID: 33670761
[TBL] [Abstract][Full Text] [Related]
4. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway.
Zhang N; Qiu J; Zheng T; Zhang X; Hua K; Zhang Y
Oncol Rep; 2018 Mar; 39(3):1034-1042. PubMed ID: 29286125
[TBL] [Abstract][Full Text] [Related]
5. The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and Metastasis.
Gründker C; Emons G
Front Endocrinol (Lausanne); 2017; 8():187. PubMed ID: 28824547
[TBL] [Abstract][Full Text] [Related]
6. Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations.
Voutsadakis IA
Clin Med Insights Oncol; 2016; 10():17-25. PubMed ID: 27053923
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase (MAPK)-dependent activation of matrix metalloproteinase (MMP)-2.
Wu HM; Wang HS; Huang HY; Lai CH; Lee CL; Soong YK; Leung PC
BMC Cancer; 2013 Jun; 13():300. PubMed ID: 23786715
[TBL] [Abstract][Full Text] [Related]
8. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.
Gründker C; Emons G
Reprod Biol Endocrinol; 2003 Oct; 1():65. PubMed ID: 14594454
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
Chatzistamou I; Schally AV; Sun B; Armatis P; Szepeshazi K
Br J Cancer; 2000 Oct; 83(7):906-13. PubMed ID: 10970693
[TBL] [Abstract][Full Text] [Related]
10. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma.
Schiffenbauer YS; Abramovitch R; Meir G; Nevo N; Holzinger M; Itin A; Keshet E; Neeman M
Proc Natl Acad Sci U S A; 1997 Nov; 94(24):13203-8. PubMed ID: 9371824
[TBL] [Abstract][Full Text] [Related]
11. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.
Kovacs M; Schally AV; Nagy A; Koppan M; Groot K
Proc Natl Acad Sci U S A; 1997 Feb; 94(4):1420-5. PubMed ID: 9037068
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
Yano T; Pinski J; Radulovic S; Schally AV
Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1701-5. PubMed ID: 8127868
[TBL] [Abstract][Full Text] [Related]
13. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.
Schally AV; Srkalovic G; Szende B; Redding TW; Janaky T; Juhasz A; Korkut E; Cai RZ; Szepeshazi K; Radulovic S
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1061-7. PubMed ID: 1981009
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis.
Schally AV
Peptides; 1999; 20(10):1247-62. PubMed ID: 10573298
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
Yano T; Pinski J; Halmos G; Szepeshazi K; Groot K; Schally AV
Proc Natl Acad Sci U S A; 1994 Jul; 91(15):7090-4. PubMed ID: 7518926
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
Radulovic S; Comaru-Schally AM; Milovanovic S; Schally AV
Pancreas; 1993 Jan; 8(1):88-97. PubMed ID: 8093555
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
